NY-LINEAGE-LOGISTICS
23.3.2020 21:09:09 CET | Business Wire | Press release
Kyrie Irving has partnered with Lineage Logistics , the world’s largest and most innovative provider of temperature-controlled logistics, and Feeding America® , the nation’s largest hunger-relief organization, to raise awareness for its Share A Meal campaign, which aims to help provide 100 million meals* in response to COVID-19. The campaign goal is to help ensure no family or child goes hungry during this global pandemic.
Kyrie is personally contributing $323,000, and is asking his family, friends, fans and partners to join him in donating in support of Feeding America’s COVID-19 Response Fund. Lineage Logistics will match all donations up to $200,000 to City Harvest, New York City’s private response to hunger and largest food rescue organization, and in addition, Kyrie and Lineage are donating over 250,000 meals** to City Harvest to immediately help those affected by COVID-19.
“Seeing the effects of COVID-19 reach our families, our schools, our jobs, and access to food has really impacted me,” said Kyrie. “I am excited to partner with Feeding America and Lineage Logistics to launch the Share A Meal campaign to help marginalized communities get the food resources they require during this time, and to work with City Harvest to distribute meals to my neighbors in need across the New York area. Thank you to everyone on the front line working to keep all of us safe, healthy, and fed. Together we can change the world one small gesture at a time."
“The COVID-19 virus presents extraordinary challenges for moving, storing, and distributing food on a large scale,” said Greg Lehmkuhl, Lineage’s President & CEO. “At Lineage, we’ve built a business dedicated to shepherding food all over the world, and that experience puts us in a unique position to help overcome these challenges. We want to do our part by sharing what we have to offer – including temperature-controlled warehouse space, supply chain logistics expertise and financial resources.”
City Harvest is dedicated to feeding New Yorkers who are struggling to put meals on their tables, and in response to the COVID-19 crisis and its devastating economic impact, the organization is stepping up to rescue and deliver more food to meet the increasing need. Deemed an essential service by Governor Cuomo and New York State, its fleet of 22 trucks will continue to be on the road, working hard to make sure all children, families, and New Yorkers in need have enough nutritious food in the coming weeks, months, and beyond.
Lineage is working with a variety of strategic partners, including Kyrie and Stephen and Ayesha Curry’s foundation, Eat. Learn. Play., to achieve its campaign goal of 100 million meals. Recognizing that COVID-19 is a worldwide crisis, Lineage is working with the Global FoodBanking Network , to provide funds, donate food, and volunteer the company’s storage resources and distribution expertise on a global scale. The Company will also leverage its expansive network of customers, which includes some of the world’s largest food producers and manufacturers, to join Lineage in its commitment to reach Share A Meal ’s ambitious goal.
To join the Share A Meal effort and support Feeding America and City Harvest, please visit http://feedingamerica.org/kyrie-covid .
*100 million meal equivalent will include financial and in-kind donations facilitated by Lineage and its partners to Feeding America and other hunger-relief organizations.
**The 250,000 meal donation is equivalent to 25,000 pounds of food being donated to City Harvest as well as a $25,000 monetary donation, according to the following calculation: $1 = 10 meals.
About Lineage Logistics
Lineage is the world’s largest and most innovative provider of temperature-controlled logistics solutions. Lineage’s expertise in end-to-end logistical solutions, its unrivaled facility network, and its use of technology combine to promote food safety, increase distribution efficiency, advance sustainability, lessen environmental impact, and minimize supply chain waste. As a result, Lineage helps customers ranging from Fortune 500 companies to small family-owned businesses increase the efficiency and protect the integrity of their temperature-controlled supply chain. In recognition of the company’s leading innovations, Lineage was recognized as the No 1. Data Science company on Fast Company’s Annual list of The World’s Most Innovative Companies in 2019, in addition to ranking 23rd overall in an evaluation of thousands of companies worldwide. For more information, visit: www.lineagelogistics.com .
About City Harvest
City Harvest is New York City’s largest food rescue organization, helping to feed the nearly 1.2 million New Yorkers who are struggling to put meals on their tables. We will rescue 66 million pounds of food this year and deliver it, free of charge, to hundreds of soup kitchens, food pantries, and other community partners across the five boroughs. Our programs empower individuals through nutrition education, increase our partners’ capacity, and strengthen the local food system, helping New Yorkers who are experiencing food insecurity to access, afford, and consume nutritious food. To learn more about our work, visit www.cityharvest.org
About Feeding America®
Feeding America® is the largest hunger-relief organization in the United States. Through a network of 200 food banks and 60,000 food pantries and meal programs, we provide meals to more than 40 million people each year. Feeding America also supports programs that prevent food waste and improve food security among the people we serve; educates the public about the problem of hunger; and advocates for legislation that protects people from going hungry. Individuals, charities, businesses and government all have a role in ending hunger. Donate. Volunteer. Advocate. Educate. Together we can solve hunger. Visit www.feedingamerica.org , find us on Facebook or follow us on Twitter .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200323005660/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
